Dr. Hoos Discusses the Clinical Kinetics of Immunotherapy

Axel Hoos, MD, PhD
Published: Friday, Jul 01, 2011

Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb discusses the need to understand the clinical kinetics of immunotherapy and how using the body's own immune system differs from the standard chemotherapy method - specifically in regards to measuring response.

Dr. Hoos says the immunotherapy community has spent time trying to identify how they can best investigate therapies and step away from the conventional chemotherapy paradigm, which is the standard for investigating cancer agents. Some progress was made in terms of understanding the clinical kinetics of immunotherapies, such as how fast they act in the patient and how to identify end points to measure those activities. That has led to an understanding of survivor kinetics.
Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb discusses the need to understand the clinical kinetics of immunotherapy and how using the body's own immune system differs from the standard chemotherapy method - specifically in regards to measuring response.

Dr. Hoos says the immunotherapy community has spent time trying to identify how they can best investigate therapies and step away from the conventional chemotherapy paradigm, which is the standard for investigating cancer agents. Some progress was made in terms of understanding the clinical kinetics of immunotherapies, such as how fast they act in the patient and how to identify end points to measure those activities. That has led to an understanding of survivor kinetics.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x